Session 7: Beyond pathology of breast cancer in 2015

Chairs: Giuseppe Viale (Italy), Hervé Bonnefoi (France)

  • The special case of “equivocal” pathological biomarkers (ER, PgR and HER2): Implications for breast cancer treatment (Fraser W. Symmans, USA)
  • BCL-2: A new therapeutic target in estrogen receptor-positive breast cancer? (Geoffrey J. Lindeman, Australia)
  • The changing role of ER in endocrine resistance (C. Kent Osborne, USA)
  • Developing Ki-67 as a useful marker (Carsten Denkert, Germany)
  • Discussion